+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.

Age: 18Years - 80YearsAll GendersPhase 3
370 locations
C

Actively Recruiting

Researchers are evaluating how well guselkumab works compared to risankizumab in people with moderately to severely active Crohns Disease, a long-term condition causing severe inflammation in the intestines. This Phase 3b study aims to compare the effectiveness and safety of these two treatments to better understand their impact on this condition. Participants will receive either guselkumab or risankizumab following specific dosing schedules. Those receiving guselkumab will get induction doses by subcutaneous injection at Weeks 0, 4, and 8, then maintenance doses every 4 weeks from Week 12 through Week 52. Participants in the risankizumab group will receive induction doses intravenously at Weeks 0, 4, and 8, followed by maintenance doses by subcutaneous injection every 8 weeks from Week 12 to Week 52. During the study, participants will be monitored for deep remission at Week 52, along with other outcomes like clinical remission, endoscopic response, and steroid-free remission. Safety will be assessed by tracking adverse events and lab test abnormalities up to Week 165. Follow-up will continue to evaluate long-term effects, with participant involvement lasting until study completion in 2030.

Age: 18Years +All GendersPhase 3
164 locations
E

Actively Recruiting

Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.

Age: 18Years +All GendersPhase 2Phase 3
395 locations
E

Actively Recruiting

Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.

Age: 18Years - 80YearsAll GendersPhase 4
101 locations
A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the Gixam device for detecting pre-cancer or cancer in the colon and rectum in adults aged 45 to 84 who are at average risk for colorectal cancer and have had a negative Fecal Immunochemical Test FIT result. The study aims to determine if the Gixam device can identify colorectal neoplasia missed by the FIT test by comparing its results to those from a standard screening colonoscopy. Participants will undergo three main procedures the Gixam test, a FIT sample collected at home and sent to a lab, and a standard screening colonoscopy. All enrolled participants will receive these interventions, with the colonoscopy serving as the reference standard to assess the accuracy of the Gixam device. The study focuses on screening and does not include treatment interventions. During the study, participants will complete the Gixam test and FIT, followed by the colonoscopy. Researchers will monitor safety from enrollment up to 30 days after, and efficacy outcomes will be assessed through study completion, averaging 30 days. The study involves evaluating test results, collecting safety data, and comparing findings to help determine if the Gixam device is a useful screening tool for colorectal cancer.

Age: 45Years - 84YearsAll GendersPhase Not Applicable
9 locations
S

Actively Recruiting

Researchers are evaluating the performance of two blood-based diagnostic aid tests designed to detect cancer in individuals aged 45 and older who show symptoms, signs, or findings that suggest possible cancer. The study focuses on cancers originating from specific sites as outlined in the protocol, aiming to establish how well these tests identify the presence of cancer compared to standard diagnostic methods. Participants will provide a blood sample for analysis by the investigational diagnostic tests. The study includes people either undergoing diagnostic work-up for suspected cancer or those recently diagnosed with cancer who have not yet received treatment. The test results will be kept blinded from investigators, clinicians, and participants, ensuring that the investigational test does not influence clinical decisions. All analyses will be done without revealing results during the study period. During the study, participants will have blood collected and undergo standard diagnostic procedures as recommended by their doctors. The research team will gather clinical outcomes based on routine care diagnostics and pathology reports. Researchers will measure how accurately the tests detect cancer and assess various test readout distributions over an 18-month period. Participants involvement includes consenting to blood draws and allowing access to diagnostic information, with no additional interventions affecting their usual care.

Age: 45Years +All Genders
42 locations